Journal: Expert review of neurotherapeutics

Article Title: Investigational drugs in recent clinical trials for treatment-resistant depression

doi: 10.1080/14737175.2017.1283217

Figure Lengend Snippet: Investigational drugs for treatment-resistant depression reviewed in this article.

Article Snippet: The study was recently completed, but results are not yet posted on ClinicalTrials.com. table ft1 table-wrap mode="anchored" t5 caption a7 Compound Sponsor Identifier Primary outcome Time frame N a Results or status Glutamatergic agents AVP-923 James Murrough (NY, USA) {"type":"clinical-trial","attrs":{"text":"NCT01882829","term_id":"NCT01882829"}} NCT01882829 MADRS e 10 W 20 March 2016 b AVP-786 Avanir (USA) {"type":"clinical-trial","attrs":{"text":"NCT02153502","term_id":"NCT02153502"}} NCT02153502 MADRS e 10 W 200 March 2016 b CERC-301 Cerecor (USA) Reference [ 84 ] HDRS-17 d 5 W 137 NS Cerecor (USA) {"type":"clinical-trial","attrs":{"text":"NCT02459236","term_id":"NCT02459236"}} NCT02459236 Bech-6 f 4 D 104 September 2016 b AV-101 National Institute of Mental Health (USA) {"type":"clinical-trial","attrs":{"text":"NCT02484456","term_id":"NCT02484456"}} NCT02484456 HDRS d Multiple 25 December 2019 b AZD6765 Astra-Zeneca (UK) Reference [ 89 ] MADRS e Multiple 22 Small, transient effect j Rapastinel Allergan (USA) {"type":"clinical-trial","attrs":{"text":"NCT01684163","term_id":"NCT01684163"}} NCT01684163 HDRS d 16 W 369 April 2014 b RO4995819 Hoffmann-La Roche (Switzerland) 2011–002160-24 g MADRS e 6 W 340 Terminated Other psychotropic drugs Ziprasidone Massachusetts General Hospital (USA) Reference [ 96 ] HDRS d 8 W 139 ZIP = 35% PL = 20% c , i Psilocybin Imperial College London (UK) Reference [ 100 ] Psychedelic PDE h 12 Ongoing Somatic drugs Minocycline Charite University (Germany) {"type":"clinical-trial","attrs":{"text":"NCT02456948","term_id":"NCT02456948"}} NCT02456948 MADRS e 6 W 160 February 2019 b Tocilizumab Brigham and Women’s Hospital (USA) {"type":"clinical-trial","attrs":{"text":"NCT02660528","term_id":"NCT02660528"}} NCT02660528 HDRS d 8 W 15 June 2017 b Sirukumab Janssen-Cilag International (Poland) 2014–005206-3 g HDRS d 12 W 192 Ongoing Open in a separate window a Enrolment (final or estimated). b Primary completion date (past or estimated). c Statistically significant. d Hamilton Depression Rating Scale. e Montgomery–Asberg Depression Rating Scale. f 6-item unidimensional subset of the HDRS-17. g Eudra identifier. h Peak drug effects. i Percent of responders (see text). j See text.

Techniques: Bioprocessing

Journal: Expert review of neurotherapeutics

Article Title: Investigational drugs in recent clinical trials for treatment-resistant depression

doi: 10.1080/14737175.2017.1283217

Figure Lengend Snippet: Investigational drugs in phase II trials for treatment-resistant depression (2014 and later).

Article Snippet: The study was recently completed, but results are not yet posted on ClinicalTrials.com. table ft1 table-wrap mode="anchored" t5 caption a7 Compound Sponsor Identifier Primary outcome Time frame N a Results or status Glutamatergic agents AVP-923 James Murrough (NY, USA) {"type":"clinical-trial","attrs":{"text":"NCT01882829","term_id":"NCT01882829"}} NCT01882829 MADRS e 10 W 20 March 2016 b AVP-786 Avanir (USA) {"type":"clinical-trial","attrs":{"text":"NCT02153502","term_id":"NCT02153502"}} NCT02153502 MADRS e 10 W 200 March 2016 b CERC-301 Cerecor (USA) Reference [ 84 ] HDRS-17 d 5 W 137 NS Cerecor (USA) {"type":"clinical-trial","attrs":{"text":"NCT02459236","term_id":"NCT02459236"}} NCT02459236 Bech-6 f 4 D 104 September 2016 b AV-101 National Institute of Mental Health (USA) {"type":"clinical-trial","attrs":{"text":"NCT02484456","term_id":"NCT02484456"}} NCT02484456 HDRS d Multiple 25 December 2019 b AZD6765 Astra-Zeneca (UK) Reference [ 89 ] MADRS e Multiple 22 Small, transient effect j Rapastinel Allergan (USA) {"type":"clinical-trial","attrs":{"text":"NCT01684163","term_id":"NCT01684163"}} NCT01684163 HDRS d 16 W 369 April 2014 b RO4995819 Hoffmann-La Roche (Switzerland) 2011–002160-24 g MADRS e 6 W 340 Terminated Other psychotropic drugs Ziprasidone Massachusetts General Hospital (USA) Reference [ 96 ] HDRS d 8 W 139 ZIP = 35% PL = 20% c , i Psilocybin Imperial College London (UK) Reference [ 100 ] Psychedelic PDE h 12 Ongoing Somatic drugs Minocycline Charite University (Germany) {"type":"clinical-trial","attrs":{"text":"NCT02456948","term_id":"NCT02456948"}} NCT02456948 MADRS e 6 W 160 February 2019 b Tocilizumab Brigham and Women’s Hospital (USA) {"type":"clinical-trial","attrs":{"text":"NCT02660528","term_id":"NCT02660528"}} NCT02660528 HDRS d 8 W 15 June 2017 b Sirukumab Janssen-Cilag International (Poland) 2014–005206-3 g HDRS d 12 W 192 Ongoing Open in a separate window a Enrolment (final or estimated). b Primary completion date (past or estimated). c Statistically significant. d Hamilton Depression Rating Scale. e Montgomery–Asberg Depression Rating Scale. f 6-item unidimensional subset of the HDRS-17. g Eudra identifier. h Peak drug effects. i Percent of responders (see text). j See text.

Techniques:

Journal: Chemie der Erde : Beitrage zur chemischen Mineralogie, Petrographie und Geologie

Article Title: Geochemistry and Cosmochemistry of Potassium Stable Isotopes

doi: 10.1016/j.chemer.2021.125786

Figure Lengend Snippet: Potassium ion-exchange separation procedure comparison

Article Snippet: Monitoring the total recovery rates and final matrix element abundances is recommended to ensure negligible column fractionation and matrix effects. table ft1 table-wrap mode="anchored" t5 caption a7 Strelow et al. (1970) Humayun and Clayton (1995b) Wang and Jacobsen (2016b) Li et al. (2016) Morgan et al. (2018) Hu et al. (2018a) Chen et al. (2019b) University of Minnesota (unpublished) Li et al. (2020) Ku and Jacobsen (2020) Moynier et al. (2021) Chen et al. (2021) Resin Bio-Rad AG50W-X8 (200–400 mesh) Bio-Rad AG50W-X8 (100–200 mesh) Bio-Rad AG50W-X8 (100–200 mesh) Bio-Rad AG50W-X12 (100–200 mesh) Dionex CS-16 cation exchange column Bio-Rad AG50W-X8 (200–400 mesh) Bio-Rad AG50W-X8 (100–200 mesh) Bio-Rad AG50W-X8 (200–400 mesh) Bio-Rad AG50W-X12 (200–400 mesh) Bio-Rad AG50W-X8 (100–200 mesh) Bio-Rad AG50W-X8 (200–400 mesh) Bio-Rad AG50W-X8 (200–400 mesh) Column Borosilicate glass Pyrex or quartz Quartz Quartz Disposable Bio-Rad Poly-Prep polyethylene column Disposable Poly-Prep Econo-Pac polyethylene column Disposable Bio-Rad Poly-Prep polyethylene column Savillex Standard micro-column Quartz Disposable Bio-Rad Poly-Prep polyethylene column Disposable Bio-Rad Poly-Prep polyethylene column I.D.

Techniques: